News Website

Lunresertib Plus Camonsertib Produces Durable Responses in Advanced Endometrial, Ovarian Cancer - OncLive

Lunresertib Plus Camonsertib Produces Durable Responses in Advanced Endometrial, Ovarian Cancer OncLive

Published: Dec. 19, 2024, 4:30 p.m.

Read Full Article

GSK’s Cancer Drug Jemperli Nears EU Marketing Expansion - MSN

GSK’s Cancer Drug Jemperli Nears EU Marketing Expansion MSN

Published: Dec. 19, 2024, 1:50 p.m.

Read Full Article

Pembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without RT for Newly Diagnosed, High-Risk Endometrial Cancer: Results in DMMR Tumors - Medpage Today

Pembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without RT for Newly Diagnosed, High-Risk Endometrial Cancer: Results in DMMR Tumors Medpage Today

Published: Dec. 18, 2024, 8:16 p.m.

Read Full Article

ASCO Reading Room | The Evolving Treatment Landscape for High-Risk Endometrial Cancer - Medpage Today

ASCO Reading Room | The Evolving Treatment Landscape for High-Risk Endometrial Cancer Medpage Today

Published: Dec. 18, 2024, 3:59 p.m.

Read Full Article

Brian Slomovitz on Adjuvant Pembrolizumab/Chemotherapy for Advanced Endometrial Cancer - Medpage Today

Brian Slomovitz on Adjuvant Pembrolizumab/Chemotherapy for Advanced Endometrial Cancer Medpage Today

Published: Dec. 18, 2024, 3:27 p.m.

Read Full Article

GSK’s Jemperli receives positive CHMP opinion for expanded endometrial cancer use - PMLiVE

GSK’s Jemperli receives positive CHMP opinion for expanded endometrial cancer use PMLiVE

Published: Dec. 18, 2024, 12:25 p.m.

Read Full Article

Molecular Classification Drives Advances in Endometrial Cancer Treatment - Journal of Clinical Pathways

Molecular Classification Drives Advances in Endometrial Cancer Treatment Journal of Clinical Pathways

Published: Dec. 17, 2024, 3:25 p.m.

Read Full Article

GSK’s Cancer Drug Jemperli Moves a Step Closer to European Marketing Permission - MSN

GSK’s Cancer Drug Jemperli Moves a Step Closer to European Marketing Permission MSN

Published: Dec. 17, 2024, 1:27 p.m.

Read Full Article

Endometrioid adenocarcinoma of the colon arising from rare malignant transformation of extra-gonadal endometrioma.

Endometriosis is a common condition with a rare malignant potential. We report a case of a patient with a colon mass who underwent surgery for malignant endometriosis associated cancer.Case: A …

Published: Dec. 17, 2024, midnight

Read Full Article

Role of pre-diagnostic reproductive factors on long-term (10 years or greater) survival of epithelial ovarian cancer: The Extreme study.

Several reproductive factors are associated with ovarian cancer risk but the association with survival is less clear. The main aim was to examine the impact of pre-diagnostic reproductive factors on …

Published: Dec. 17, 2024, midnight

Read Full Article

cohort study long-term survival nationwide ovarian cancer reproductive factors

Latest Articles

Lunresertib Plus Camonsertib Produces Durable Responses in Advanced Endometrial, Ovarian Cancer - OncLive

GSK’s Cancer Drug Jemperli Nears EU Marketing Expansion - MSN

Pembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without RT for Newly Diagnosed, High-Risk Endometrial Cancer: Results in DMMR Tumors - Medpage Today

ASCO Reading Room | The Evolving Treatment Landscape for High-Risk Endometrial Cancer - Medpage Today

Brian Slomovitz on Adjuvant Pembrolizumab/Chemotherapy for Advanced Endometrial Cancer - Medpage Today

GSK’s Jemperli receives positive CHMP opinion for expanded endometrial cancer use - PMLiVE

Molecular Classification Drives Advances in Endometrial Cancer Treatment - Journal of Clinical Pathways

GSK’s Cancer Drug Jemperli Moves a Step Closer to European Marketing Permission - MSN

Endometrioid adenocarcinoma of the colon arising from rare malignant transformation of extra-gonadal endometrioma.

Role of pre-diagnostic reproductive factors on long-term (10 years or greater) survival of epithelial ovarian cancer: The Extreme study.

Subscribe to Our Newsletter